BCI
CERE

Bain Capital Investors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Bain Capital Investors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-65,679,781
Closed -$2.69B – 6
2024
Q2 		$2.69B Hold
65,679,781
– – 57.02% 1
2024
Q1 		$2.78B Hold
65,679,781
– – 61.94% 1
2023
Q4 		$2.78B Buy
65,679,781
+5,480,052
+9% +$157M 60.39% 1
2023
Q3 		$1.31B Hold
60,199,729
– – 42.08% 2
2023
Q2 		$1.91B Sell
60,199,729
-432,627
-0.7% -$13.3M 28.7% 3
2023
Q1 		$1.48B Hold
60,632,356
– – 26.92% 3
2022
Q4 		$1.91B Hold
60,632,356
– – 41.46% 1
2022
Q3 		$1.71B Hold
60,632,356
– – 41.39% 1
2022
Q2 		$1.6B Hold
60,632,356
– – 33.55% 1
2022
Q1 		$2.12B Hold
60,632,356
– – 30.71% 2
2021
Q4 		$1.97B Hold
60,632,356
– – 23.51% 3
2021
Q3 		$1.79B Hold
60,632,356
– – 21.09% 3
2021
Q2 		$1.55B Hold
60,632,356
– – 15.17% 3
2021
Q1 		$832M Hold
60,632,356
– – 12.25% 4
2020
Q4 		$1.01B Buy
+60,632,356
New +$788M 38.09% 1

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Bain Capital Investors's CERE Position: Q3 2024 in Review

Bain Capital Investors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 65,679,781 shares — an estimated $2.69B sold.

Bain Capital Investors first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $2.78B in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Bain Capital Investors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Bain Capital Investors sold 65,679,781 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $2.69B.
  • Bain Capital Investors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Bain Capital Investors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $2.78B in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Bain Capital Investors's 13F filing for Q3 2024, filed 14 Nov 2024.